Tamiflu Data Called Inconsistent, Underreported
January 20, 2012 — An international team of medical experts is calling into question the safety and efficacy of the anti-influenza drug oseltamivir (Tamiflu), saying that a review of unpublished data shows inconsistencies and that the drug’s maker, Roche, has failed to provide access to a substantial amount of data on the drug. The review was published online January 18 in the Cochrane Library.
Roche has recorded billions in sales of Tamiflu. Now there are reports of reporting bias and failure to report the correct conclusions of the drug’s efficacy:
While on one hand, Tamiflu is stockpiled globally as a defense against pandemic influenza, on the other hand, doubts are being raised over the efficacy of this medical arsenal against flu.
According to a new report by The Cochrane Collaboration, which reviewed the randomized controlled trial evidence of neuraminidase inhibitors like Tamiflu in treating and preventing influenza, there is a high risk of publication and reporting biases in the trial program of Tamiflu.
The PR department at Roche has been hitting back:
Roche, the manufacturer of Tamiflu, sent a response to the Cochrane Collaboration report:
About Tamiflu safety and effectiveness:
Tamiflu is an oral antiviral proven to be effective and generally well-tolerated for the treatment and prevention of influenza in adults and children one year of age and older.
Unlike over-the-counter medicines that relieve only symptoms, the antiviral Tamiflu acts by stopping the influenza virus from spreading and is active at sites in the body where the influenza virus multiplies. Tamiflu is effective against most clinically-relevant influenza viruses, including A(H1N1) and A(H5N1) strains. Numerous clinical trials and real-life medical experience show Tamiflu is effective in reducing the severity and duration of influenza symptoms as well as specified secondary complications. Analysis by health authorities and independent research groups show that, during the 2009 H1N1 pandemic, Tamiflu saved lives and reduced hospitalization. Similar benefits have also been reported for seasonal influenza.
But the truly damning statement is laconic and comes from the Cochrane Collaboration:
All the studies were sponsored by manufacturers of NIs (note: Neuraminidase Inhibitors)
.
No independent analysis, just self-interest and billions of dollars of sales as governments stockpile a drug of questionable efficacy. Big money = big political influence = no big surprise.